Build status - In Progress

Study Comparing the Effect of Drug Abelacimab Relative to Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Gastrointestinal (GI) / Genitourinary (GU) Cancer Associated VTE

Recruiting
18 years - 99 years
All
Phase 3
1 Location

Brief description of study

This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of $1,000.00 (10 total visits).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Venous Thromboembolism,VTE,gastrointestinal,genitourinary
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 851763

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center